
ALPS Medical Breakthroughs ETF
ALPS Medical Breakthroughs ETF (SBIO) Price & Chart
SBIO ETF Chart & Stats
- Day’s Range
- $54.50 - $55.83
- 52-Week Range
- $44.80 - $70.85
- Previous Close
- $55.91
- Volume
- 11.84K
- Average Volume (3M)
- 36.92K
- AUM
- 187.10M
- NAV
- 55.60
- Expense Ratio
- 0.50%
- Holdings Count
- 102
- Beta
- 1.08
- Inception Date
- Dec 31, 2014
- Last Dividend Ex-Date
- Dec 19, 2024
- Dividend Yield
- (2.11%)
- Shares Outstanding
- 3,350,000
- Standard Deviation
- N/A
ETF Overview
ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an innovative investment vehicle designed for those looking to capitalize on the dynamic and rapidly evolving biotechnology sector within the broader health care category. This ETF uniquely focuses on small to mid-cap biotechnology companies that are poised at the forefront of medical advancements, particularly those engaged in the development of groundbreaking treatments and therapies. By targeting firms with drugs in Phase II and Phase III clinical trials, SBIO offers exposure to companies on the cusp of delivering potentially transformative health care solutions. Investors interested in the cutting-edge of medical innovation will appreciate SBIO's strategic approach, which combines focused sector expertise with the potential for high growth. As the global demand for advanced medical treatments continues to rise, this ETF provides a curated portfolio that taps into the heart of scientific discovery and medical progress. With the ALPS Medical Breakthroughs ETF, investors are not just buying into stocks; they are investing in the future of health care and the promise of revolutionary therapies that could redefine medical treatment paradigms.
- Asset Class
- Equity
- Region
- North America
- Issuer
- ALPS
- Index Tracked
- S-Network Medical Breakthroughs Index
- Ticker Symbol
- SBIO
SBIO ETF News


CG Oncology (CGON) announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta less than or equal

Amylyx (AMLX) Pharmaceuticals will present the results from the 16-week double-blind treatment period of the Phase 3 Lucidity clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor antagonist, in

SBIO ETF FAQ
What was SBIO’s price range in the past 12 months?
What is the AUM of SBIO?
Is SBIO overvalued?
Does SBIO pay dividends?
How many shares outstanding does SBIO have?
SBIO ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| ORKAOruka Therapeutics, Inc. | 4.58% |
| CGONCG Oncology, Inc. | 4.33% |
| MANEVeradermics, Incorporated | 3.56% |
| DNTHDianthus Therapeutics, Inc. | 3.37% |
| EWTXEdgewise Therapeutics, Inc. | 3.27% |
| TVTXTravere Therapeutics, Inc. | 3.13% |
| DFTXDefinium Therapeutics, Inc. | 2.83% |
| RLAYRelay Therapeutics Inc | 2.61% |
| XENEXenon Pharmaceuticals | 2.58% |
| AMLXAmylyx Pharmaceuticals, Inc. | 2.50% |
| Total | 32.76% |








